Profound Medical to Host Investor Call to Discuss First Clinical Outcomes from the CAPTAIN Trial on March 13; Participate in ROTH Investor Conference on March 22-24
MWN-AI** Summary
Profound Medical Corp. (NASDAQ:PROF; TSX:PRN), a Toronto-based commercial-stage medical device company specializing in AI-powered, MRI-guided therapies, is set to present the first clinical outcomes from the CAPTAIN trial, which compares the safety and efficacy of the TULSA Procedure™ against robotic radical prostatectomy for men with localized prostate cancer. This presentation will take place on March 13, 2026, at the 41st Annual European Association of Urology (EAU 2026) Congress in London, UK, at 9:40 a.m. EDT. Notable urologist Dr. Laurence Klotz will lead the presentation, sharing insights on the trial's findings.
Following the presentation, Profound will host an investor webinar at 11:30 a.m. EDT, where Dr. Klotz will delve deeper into the implications of the CAPTAIN data, alongside Profound's management discussing the commercial prospects of the TULSA Procedure and its potential integration into prostate cancer treatment guidelines. Interested investors must register in advance for this live webinar.
Additionally, Profound Medical plans to participate in one-on-one meetings at the 38th Annual Roth Conference, scheduled from March 22-24, 2026, in Dana Point, California. Investors wishing to engage with Profound’s management can coordinate through their Roth representative.
Profound Medical's flagship TULSA-PRO® system provides precise, incision-free prostate therapy, allowing real-time visualization and treatment confirmation, thereby reducing side effects typically seen with traditional treatments. The company also markets Sonalleve®, an MRI-guided therapy for various conditions, exemplifying their commitment to advancing innovative, personalized treatment options while minimizing recovery time and complications. Profound's technologies are approved for use in key global markets, emphasizing their role in leading the future of MRI-guided therapies.
MWN-AI** Analysis
Profound Medical Corp. (NASDAQ: PROF; TSX: PRN) presents an intriguing investment opportunity as it gears up to reveal pivotal clinical outcomes from its CAPTAIN trial on March 13, 2026. This trial compares the TULSA Procedure™, a pioneering MRI-guided, incision-free treatment for localized prostate cancer, with the traditional robotic radical prostatectomy. With seasoned urologist Dr. Laurence Klotz leading the presentation at the EAU 2026 Congress, market participants should closely monitor the data unveiled, which has the potential to significantly impact treatment guidelines and adoption rates for the TULSA Procedure.
The investor call following the presentation is a critical juncture, allowing management to address the clinical relevance of the findings and outline strategic commercial implications. The outcomes could bolster Profound’s position within the increasingly competitive prostate cancer treatment landscape, particularly if the efficacy and safety profile of the TULSA Procedure demonstrates a marked advantage over conventional surgical methods. Strong results may enhance investor sentiment and catalyze further institutional interest, especially as the procedure seeks inclusion in treatment guidelines.
Additionally, Profound's participation in the upcoming ROTH Conference from March 22-24 provides further avenues for engagement with potential investors. One-on-one meetings present an opportunity for the company's management to convey their strategic vision and discuss growth prospects directly with investors.
For shareholders and prospective investors, watching the outcomes of the CAPTAIN trial and the subsequent market reactions will be vital. Should the data support the TULSA Procedure's advancements, Profound Medical could see a substantial uptick in valuation and market penetration in the coming quarters. Therefore, positioning in Profound Medical may be prudent, aligning with their innovative approach to improved patient outcomes in prostate cancer treatment.
**MWN-AI Summary and Analysis is based on asking OpenAI to summarize and analyze this news release.
TORONTO, March 09, 2026 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets AI-powered, MRI-guided, incision-free therapies for the ablation of diseased tissue, today announced that the first clinical outcomes from the Level 1 post-market CAPTAIN trial comparing the safety and efficacy of the TULSA Procedure™ with robotic radical prostatectomy in men with localized prostate cancer are scheduled to be presented during the Late-Breaking and High-Impact session at the 41st Annual European Association of Urology (“EAU 2026”) Congress in London, UK on March 13, 2026 at 9:40 a.m. EDT (1:40 p.m. GMT).
The EAU 2026 CAPTAIN study presentation will be given by Laurence Klotz, CM, MD, FRCSC, an esteemed urologist, a professor of surgery at the University of Toronto, the Sunnybrook Chair of Prostate Cancer Research, and one of the investigators for the trial.
Profound plans to issue a press release summarizing the EAU 2026 CAPTAIN presentation as soon as practicable following its conclusion on Friday morning, and then host an investor webinar at 11:30 a.m. EDT, during which Dr. Klotz will review the CAPTAIN data and its clinical relevance, and Profound management will discuss the commercial implications of the data and next steps in advancing the TULSA Procedure toward potential inclusion in prostate cancer treatment guidelines.
Details of Investor Call to Discuss the First CAPTAIN Trial Clinical Outcomes
IMPORTANT – Advanced registration is required to participate in the live webinar
When: March 13, 2026
Time: 11:30 a.m. EDT
Registration Link: https://kilmerlucas.zoom.us/meeting/register/zblbafrFS8qj5NQXQKYtJA
ROTH Conference
Profound also announced that management will participate in a series of one-on-one investor meetings at the 38th Annual Roth Conference to be held March 22-24, 2026 in Dana Point, California. Any attendees interested in meeting with Profound’s management team at the conference should contact their ROTH representative or email skilmer@profoundmedical.com. Due the format of the event, no webcast will be available.
About Profound Medical Corp.
Profound is a commercial-stage medical device company and an innovator in interventional MRI procedures, enabling precise, incision-free therapies that improve clinical confidence, procedural control, and patient outcomes. By leveraging real-time MRI guidance, Profound’s technologies are designed to replace uncertainty with clarity across treatment planning, delivery, and confirmation.
The company’s flagship platform, TULSA-PRO®, enables MRI-guided, incision-free prostate therapy designed for precision and flexibility. The TULSA Procedure™ allows physicians to see, treat, and confirm therapy in real time, supporting personalized treatment strategies across the continuum of prostate care—from whole-gland to subtotal, hemi, multifocal, and focal treatment. This approach enables individualized care for the full spectrum of prostate disease, including prostate cancer and/or benign prostatic hyperplasia (BPH), while minimizing side effects typically associated with surgery or radiation, such as urinary incontinence and/or erectile dysfunction.
Profound also commercializes Sonalleve®, an MRI-guided therapy that provides a non-surgical treatment option for pain palliation of bone metastases, desmoid tumors, and osteoid osteoma, as well as for common gynecologic conditions including uterine fibroids and adenomyosis. Sonalleve delivers targeted therapy with no incisions, no blood loss during the procedure, no overnight hospital stay, and faster recovery — and, in gynecologic applications, enables uterine-sparing treatment that may help preserve fertility. Profound is also exploring additional clinical applications for Sonalleve, including non-invasive ablation of abdominal cancers and hyperthermia-based cancer therapies.
Profound Medical’s technologies are approved across major global markets. TULSA-PRO is cleared or approved in the United States, Europe, Canada, Saudi Arabia, India, Australia/New Zealand, and the UAE, while Sonalleve is cleared or approved in the United States (HDE), Europe, Canada, China, and Saudi Arabia.
Through real-time MRI guidance and data-driven innovation, Profound is advancing the future of MRI-guided therapy — expanding access to precise, personalized, and incision-free treatment options worldwide.
For further information, please contact:
Stephen Kilmer
Investor Relations
skilmer@profoundmedical.com
T: 647.872.4849
FAQ**
How do the clinical outcomes from the Level 1 CAPTAIN trial impact the future market positioning of Profound Medical Corp. (NASDAQ: PROF; TSX: PRN) in the prostate cancer treatment landscape?
What are the potential commercial implications for Profound Medical Corp. (PROF) following the presentation of the CAPTAIN trial results at the EAU 20Congress?
Can Profound Medical Corp. (PROF) elaborate on the expected timeline for the potential inclusion of the TULSA Procedure™ in prostate cancer treatment guidelines after the CAPTAIN study presentation?
What strategic advantages does Profound Medical Corp. (PROF) have in expanding the adoption of the TULSA-PRO® therapy compared to traditional surgical approaches for prostate disease?
**MWN-AI FAQ is based on asking OpenAI questions about Profound Medical Corp. (TSXC: PRN:CC).
NASDAQ: PRN:CC
PRN:CC Trading
0.45% G/L:
$11.28 Last:
9,800 Volume:
$11.23 Open:
